Search Results - "Sharman, J. P."

Antibody-drug conjugates for previously treated aggressive lymphomas: focus on polatuzumab vedotin by Burke, J M, Morschhauser, F, Andorsky, D, Lee, C, Sharman, J P

“…Antibody-drug conjugates (ADCs) are immunoconjugates and comprise a monoclonal antibody that is chemically attached to a cytotoxic drug (or payload) via a…”
Get more information

A phase 2 study of zanubrutinib in previously treated B‐cell malignancies intolerant to ibrutinib and/or acalabrutinib: Preliminary results for patients with CLL/SLL by Shadman, M., Burke, J. M., Zafar, S. F., Misleh, J., Rao, S. S., Farber, C. M., Cohen, A., Crescenzo, R., By, K., Flinn, I. W., Sharman, J. P.

Get full text

CIRCULATING TUMOR DNA (CTDNA) STATUS AND CLINICAL OUTCOMES IN PATIENTS (PTS) WITH PREVIOUSLY UNTREATED DIFFUSE LARGE B‐CELL LYMPHOMA (DLBCL) IN THE POLARIX STUDY by Herrera, A. F., Tracy, S., Sehn, L. H., Jardin, F., Lenz, G., Trněný, M., Salles, G., Flowers, C. R., Tilly, H., Sharman, J. P., Friedberg, J. W., Balasubramanian, S., Raghavan, V., Hirata, J., Lee, C., Jiang, Y., Morschhauser, F.

Get full text

PRELIMINARY RESULTS OF THE PHASE 2 STUDY OF ZANUBRUTINIB IN PATIENTS WITH PREVIOUSLY TREATED B‐CELL MALIGNANCIES INTOLERANT TO IBRUTINIB AND/OR ACALABRUTINIB by Shadman, M., Sharman, J. P., Levy, M. Y., Porter, R., Zafar, S. F., Burke, J. M., Chaudhry, A., Freeman, B., Misleh, J., Yimer, H. A., Cultrera, J. L., Guthrie, T. H., Kingsley, E., Rao, S. S., Chen, D. Y., Zhang, X., Idoine, A., Cohen, A., Feng, S., Huang, J., Flinn, I.

Get full text

Vemurafenib Response in 2 Patients With Posttransplant Refractory BRAF V600E–Mutated Multiple Myeloma by Sharman, J.P, Chmielecki, J, Morosini, D, Palmer, G.A, Ross, J.S, Stephens, P.J, Stafl, J, Miller, V.A, Ali, S.M

Get full text

PB1864: BRUIN CLL‐321: A PHASE 3 OPEN‐LABEL, RANDOMIZED STUDY OF PIRTOBRUTINIB VS INVESTIGATOR'S CHOICE OF IDELALISIB+RITUXIMAB OR BENDAMUSTINE+RITUXIMAB IN BTKI PRETREATED CLL/SLL (TRIAL IN PROGRESS) by Sharman, J. P., Jurczak, W., Coombs, C. C., Hill, M., Wang, D., Ku, N. C., Guntur, A., Shahda, S., Leow, C. C., Ghia, P., Mato, A. R.

Get full text

PB1890: ZANUBRUTINIB IN ACALABRUTINIB‐INTOLERANT PATIENTS (PTS) WITH B‐CELL MALIGNANCIES by Shadman, M., Flinn, I. W., Kingsley, E. C., Freeman, B., Levy, M. Y., Cultrera, J., Farber, C. M., Chaudhry, A., Porter, R., Crescenzo, R., Idoine, A., Zhang, X., Cohen, A., By, K., Huang, J., Sharman, J. P.

Get full text

P1156: MAGNIFY PHASE 3B STUDY OF LENALIDOMIDE + RITUXIMAB (R2) FOLLOWED BY MAINTENANCE IN RELAPSED/REFRACTORY INDOLENT NON‐HODGKIN LYMPHOMA: COMPLETE INDUCTION PHASE ANALYSIS by Lansigan, F., Andorsky, D. J., Coleman, M., Yacoub, A., Melear, J. M., Fanning, S. R., Kolibaba, K. S., Reynolds, C., Nowakowski, G. S., Gharibo, M., Ahn, J. R., Li, J., Rummel, M. J., Sharman, J. P.

Get full text

P1100: BRUIN MCL‐321: A PHASE 3 OPEN‐LABEL, RANDOMIZED STUDY OF PIRTOBRUTINIB VS INVESTIGATOR CHOICE OF BTK INHIBITOR IN PATIENTS WITH PREVIOUSLY TREATED, BTK INHIBITOR NAÏVE MCL (TRIAL IN PROGRESS) by Eyre, T. A., Shah, N. N., Le Gouill, S., Dreyling, M., Vandenberghe, E., Jurczak, W., Wang, Y., Cheah, C. Y., Gandhi, M., Chay, C., Sharman, J. P., Andorsky, D. J., Yin, M., Balbas, M., Kherani, J., Wang, M. L.

Get full text

P666: ACALABRUTINIB ± OBINUTUZUMAB VS OBINUTUZUMAB + CHLORAMBUCIL IN TREATMENT‐NAIVE CHRONIC LYMPHOCYTIC LEUKEMIA: 5‐YEAR FOLLOW‐UP OF ELEVATE‐TN by Sharman, J. P., Egyed, M., Jurczak, W., Skarbnik, A., Patel, K., Flinn, I. W., Kamdar, M., Munir, T., Walewska, R., Fogliatto, L. M., Herishanu, Y., Banerji, V., Follows, G., Walker, P., Karlsson, K., Ghia, P., Janssens, A., Cymbalista, F., Ferrant, E., Wierda, W. G., Munugalavadla, V., Yu, T., Wang, M. H., Woyach, J. A.

Get full text

P1192: ASIA SUBPOPULATION ANALYSIS FROM THE PHASE III POLARIX TRIAL by Song, Y., Jin, J., Tilly, H., Zhang, H., Cao, J., Feng, J., Zhang, L., Rai, S., Goto, H., Terui, Y., Kim, W. S., Shin, H.‐J., Gau, J.‐P., Tsai, C.‐H., Sharman, J. P., Bu, L., Hirata, J., Lee, C., Izutsu, K., Zhu, J.

Get full text

P1101: PIRTOBRUTINIB, A HIGHLY SELECTIVE, NON‐COVALENT (REVERSIBLE) BTK INHIBITOR IN PREVIOUSLY TREATED MANTLE CELL LYMPHOMA: UPDATED RESULTS FROM THE PHASE 1/2 BRUIN STUDY by Eyre, T. A., Wang, M. L., Shah, N. N., Alencar, A. J., Gerson, J. N., Patel, M. R., Fakhri, B., Vandenberghe, E., Jurczak, W., Tan, X. N., Lewis, K. L., Fenske, T., Wang, Y., Coombs, C. C., Flinn, I., Lewis, D., Le Gouill, S., Gandhi, M., Chay, C., Palomba, M. L., Woyach, J. A., Pagel, J. M., Lamanna, N., Sharman, J. P., Andorsky, D. J., Cohen, J. B., Barve, M. A., Ghia, P., Yin, M., Zinzani, P. L., Ujjani, C., Koh, Y., Izutsu, K., Lech‐Maranda, E., Kherani, J., Tam, C., Sundaram, S., Nair, B., Tsai, D. E., Balbas, M., Mato, A. R., Cheah, C. Y.

Get full text

INDUCTION R2 FOLLOWED BY MAINTENANCE IN PATIENTS WITH RELAPSED/REFRACTORY MANTLE CELL LYMPHOMA: INTERIM ANALYSIS FROM THE PHASE 3B MAGNIFY STUDY by JP Sharman, JM Melear, A Yacoub, SR Fanning, DJ Andorsky, GS Nowakowski, MJ Rummel, F Lansigan, J Li, JR Ahn, M Gharibo, M Coleman

“…Objectives: The combination of lenalidomide + rituximab (R2) has shown complementary clinical activity and is a tolerable regimen in both untreated and…”
Get full text

SUBGROUP ANALYSES OF ELDERLY PATIENTS AGED 70 YEARS IN MAGNIFY: A PHASE 3B INTERIM ANALYSIS OF INDUCTION R2 FOLLOWED BY MAINTENANCE IN RELAPSED/REFRACTORY INDOLENT NON-HODGKIN LYMPHOMA by F Lansigan, DJ Andorsky, M Coleman, A Yacoub, JMM Md, SR Fanning, KS Kolibaba, C Reynolds, G Nowakowski, M Gharibo, E Ahn, J Li, MJ Rummel, JP Sharman

“…Objectives: Lenalidomide combined with rituximab (R2) has shown complimentary clinical activity and is a tolerable regimen in both untreated and relapsed or…”
Get full text

PATIENTS WITH RELAPSED/REFRACTORY MARGINAL ZONE LYMPHOMA IN THE MAGNIFY PHASE 3B INTERIM ANALYSIS OF INDUCTION R2 FOLLOWED BY MAINTENANCE by M Coleman, DJ Andorsky, A Yacoub, JM Melear, SR Fanning, KS Kolibaba, F Lansigan, C Reynolds, G Nowakowski, M Gharibo, E Ahn, J Li, MJ Rummel, JP Sharman

“…Objectives: Relapse is expected when treating patients with follicular lymphoma (FL) and marginal zone lymphoma (MZL), with a shortened response associated…”
Get full text

Polatuzumab Vedotin in Previously Untreated Diffuse Large B-Cell Lymphoma by Tilly, Hervé, Morschhauser, Franck, Sehn, Laurie H, Friedberg, Jonathan W, Trněný, Marek, Sharman, Jeff P, Herbaux, Charles, Burke, John M, Matasar, Matthew, Rai, Shinya, Izutsu, Koji, Mehta-Shah, Neha, Oberic, Lucie, Chauchet, Adrien, Jurczak, Wojciech, Song, Yuqin, Greil, Richard, Mykhalska, Larysa, Bergua-Burgués, Juan M, Cheung, Matthew C, Pinto, Antonio, Shin, Ho-Jin, Hapgood, Greg, Munhoz, Eduardo, Abrisqueta, Pau, Gau, Jyh-Pyng, Hirata, Jamie, Jiang, Yanwen, Yan, Mark, Lee, Calvin, Flowers, Christopher R, Salles, Gilles

“…The treatment outcome for diffuse large B-cell lymphoma has not been improved in nearly 20 years. However, the replacement of vincristine in R-CHOP with…”
Get full text

17th International Conference on Malignant Lymphoma, Palazzo dei Congressi, Lugano, Switzerland, 13 - 17 June, 2023 by Shadman, M, Burke, J M, Zafar, S F, Misleh, J, Rao, S S, Farber, C M, Cohen, A, Crescenzo, R, By, K, Flinn, I W, Sharman, J P

Get full text

Phase I study of single-agent CC-292, a highly selective Bruton's tyrosine kinase inhibitor, in relapsed/refractory chronic lymphocytic leukemia by Brown, Jennifer R, Harb, Wael A, Hill, Brian T, Gabrilove, Janice, Sharman, Jeff P, Schreeder, Marshall T, Barr, Paul M, Foran, James M, Miller, Thomas P, Burger, Jan A, Kelly, Kevin R, Mahadevan, Daruka, Ma, Shuo, Li, Yan, Pierce, Daniel W, Barnett, Evelyn, Marine, Jeffrey, Miranda, Monika, Azaryan, Ada, Yu, Xujie, Nava-Parada, Pilar, Mei, Jay, Kipps, Thomas J

Get full text

INDUCTION R 2 FOLLOWED BY MAINTENANCE IN PATIENTS WITH RELAPSED/REFRACTORY TRANSFORMED FOLLICULAR LYMPHOMA: INTERIM ANALYSIS FROM THE PHASE 3B MAGNIFY STUDY by . Lansigan, F, . Parameswaran, V, . Yacoub, A, . Reynolds, C. M, . Shao, S. H, . Moore, S. G, . Coleman, M, . Andorsky, D. J, . Nowakowski, G. S, . Rummel, M. J, . Li, J, . Ahn, J. R, . Gharibo, M, . Sharman, J. P

Get full text

INDUCTION R 2 FOLLOWED BY MAINTENANCE IN PATIENTS WITH RELAPSED/REFRACTORY MANTLE CELL LYMPHOMA: INTERIM ANALYSIS FROM THE PHASE 3B MAGNIFY STUDY by Sharman, J. P., Melear, J. M., Yacoub, A., Fanning, S. R., Andorsky, D. J., Nowakowski, G. S., Rummel, M. J., Lansigan, F., Li, J., Ahn, J. R., Gharibo, M., Coleman, M.

Get full text